Research programme: CRM197 fusion constructs - Turing PharmaceuticalsAlternative Names: Cross reacting material 197 fusion constructs - Turing; Diphtheria toxin fusion constructs - Turing Pharmaceuticals
Latest Information Update: 28 Nov 2015
At a glance
- Originator Turing Pharmaceuticals
- Developer The Hospital for Sick Children; Turing Pharmaceuticals
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 12 Nov 2015 Early research in Undefined indication in USA (unspecified route)